View in Other Languages 2011년 12월 7일 아시아 현장보고서: Great Wall Motors (HKG:2333), Voleex C30과 Voleex C20R의 EU 통합인증(WVTA) 확보 2011年12月7日亚洲活动报告:长城汽车(HKG:2333)腾翼C30和腾翼C20R获欧盟整车型式认证 Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R アジア市場活動レポート 2011年12月7日:グレートウォールモーターズ (Great Wall Motors) (HKG:2333) が Voleex C30 と Voleex C20R に対する EU 包括車両承認を取得 2011年12月7日亞洲活動報告:長城汽車(HKG:2333)騰翼C30和騰翼C20R獲歐盟整車型式認證 
Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R
Asian Activities Report for December 7, 2011: Great Wall Motors (HKG:2333) Receives EU Whole Vehicle Type Approval for Voleex C30 and Voleex C20R

Sydney, Dec 7, 2011 AEST (ABN Newswire) - Great Wall Motors (googlechartHKG:2333) has received EU Whole Vehicle Type Approval for its Voleex C30 and Voleex C20R. Voleex C30, Great Wall's first three-box car, is one of the Top 10 Compact Family Cars in terms of sales volume in China in 2011, and has already been sold to more than 50 countries and regions. Voleex C20R, a cross vehicle type featuring sports characteristics and multiple functions, provides superior comfort and driving excitement.

Chevalier International Holdings Limited (googlechartHKG:0025) has entered into a letter of intent in relation to possible acquisitions of certain hot spring hotels in Japan. Chevalier International is principally engaged in construction and engineering, insurance and investment, property development and investment, food and beverages, and computer and information communication technology. The acquisition, if completed, will help Chevalier diversify its income stream and gain from the development of the Japanese tourism industry.

Daiichi Sankyo Co., Ltd (googlechartTYO:4568) advises that its subsidiary Ranbaxy Laboratories Ltd. (googlechartBOM:500359), India's largest pharmaceutical company, has received final approval from the U.S. Food and Drug Administration to manufacture and market Atorvastatin, a cholesterol-reducing medicine, in the US market. Atorvastatin will provide a safe, effective, affordable and accessible alternative to Pfizer's (googlechartNYSE:PFE) cholesterol-lowering medication Lipitor, which generated total annual sales of US$7.89 billion in the US through September 2011.

Contact

Qiubei Fu
Asia Business News
Tel: +61-2-9247-4344
http://www.abnnewswire.net


ABN Newswire
ABN Newswire This Page Viewed:  (Last 7 Days: 15) (Last 30 Days: 58) (Since Published: 9435) 

View in Other Languages 96569506943591968316 (46109)

googlechart